Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamides.
Biswas K, Li A, Chen JJ, D'Amico DC, Fotsch C, Han N, Human J, Liu Q, Norman MH, Riahi B, Yuan C, Suzuki H, Mareska DA, Zhan J, Clarke DE, Toro A, Groneberg RD, Burgess LE, Lester-Zeiner D, Biddlecome G, Manning BH, Arik L, Dong H, Huang M, Kamassah A, Loeloff R, Sun H, Hsieh FY, Kumar G, Ng GY, Hungate RW, Askew BC, Johnson E. Biswas K, et al. Among authors: kumar g. J Med Chem. 2007 May 3;50(9):2200-12. doi: 10.1021/jm070055c. Epub 2007 Apr 5. J Med Chem. 2007. PMID: 17408249
A new class of bradykinin 1 receptor antagonists containing the piperidine acetic acid tetralin core.
Fotsch C, Biddlecome G, Biswas K, Chen JJ, D'Amico DC, Groneberg RD, Han NB, Hsieh FY, Kamassah A, Kumar G, Lester-Zeiner D, Liu Q, Mareska DA, Riahi BB, Wang YJ, Yang K, Zhan J, Zhu J, Johnson E, Ng G, Askew BC. Fotsch C, et al. Among authors: kumar g. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2071-5. doi: 10.1016/j.bmcl.2006.01.069. Epub 2006 Feb 7. Bioorg Med Chem Lett. 2006. PMID: 16464576
Aryl sulfones as novel bradykinin B1 receptor antagonists for treatment of chronic pain.
Biswas K, Aya T, Qian W, Peterkin TA, Chen JJ, Human J, Hungate RW, Kumar G, Arik L, Lester-Zeiner D, Biddlecome G, Manning BH, Sun H, Dong H, Huang M, Loeloff R, Johnson EJ, Askew BC. Biswas K, et al. Among authors: kumar g. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4764-9. doi: 10.1016/j.bmcl.2008.07.108. Epub 2008 Jul 31. Bioorg Med Chem Lett. 2008. PMID: 18706809
3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.
Chen JJ, Nguyen T, D'Amico DC, Qian W, Human J, Aya T, Biswas K, Fotsch C, Han N, Liu Q, Nishimura N, Peterkin TA, Yang K, Zhu J, Riahi BB, Hungate RW, Andersen NG, Colyer JT, Faul MM, Kamassah A, Wang J, Jona J, Kumar G, Johnson E, Askew BC. Chen JJ, et al. Among authors: kumar g. Bioorg Med Chem Lett. 2011 Jun 1;21(11):3384-9. doi: 10.1016/j.bmcl.2011.03.115. Epub 2011 Apr 7. Bioorg Med Chem Lett. 2011. PMID: 21514825
Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr.
Dominguez C, Smith L, Huang Q, Yuan C, Ouyang X, Cai L, Chen P, Kim J, Harvey T, Syed R, Kim TS, Tasker A, Wang L, Zhang M, Coxon A, Bready J, Starnes C, Chen D, Gan Y, Neervannan S, Kumar G, Polverino A, Kendall R. Dominguez C, et al. Among authors: kumar g. Bioorg Med Chem Lett. 2007 Nov 1;17(21):6003-8. doi: 10.1016/j.bmcl.2007.07.077. Epub 2007 Aug 22. Bioorg Med Chem Lett. 2007. PMID: 17869515
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
Potashman MH, Bready J, Coxon A, DeMelfi TM Jr, DiPietro L, Doerr N, Elbaum D, Estrada J, Gallant P, Germain J, Gu Y, Harmange JC, Kaufman SA, Kendall R, Kim JL, Kumar GN, Long AM, Neervannan S, Patel VF, Polverino A, Rose P, Plas Sv, Whittington D, Zanon R, Zhao H. Potashman MH, et al. J Med Chem. 2007 Sep 6;50(18):4351-73. doi: 10.1021/jm070034i. Epub 2007 Aug 15. J Med Chem. 2007. PMID: 17696416
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R. Polverino A, et al. Among authors: kumar g. Cancer Res. 2006 Sep 1;66(17):8715-21. doi: 10.1158/0008-5472.CAN-05-4665. Cancer Res. 2006. PMID: 16951187
4,173 results